[ad_1]
DUBAI: Hospital operator Burjeel Holdings will offer patients advanced molecular genetics, cellular and immunology testing in the UAE following a partnership with Canadian specialist laboratory operator OncoHelix Inc.
This will lead them to offer “personalized medicine” to clinics and hospitals in the UAE. Burjeel expects the new laboratory to be operational by the end of the year and will expand its ability to support hospitals in the region.
An advanced diagnostics laboratory will provide molecular genetic and immunological analysis tests to assist oncologists and physicians in the diagnosis, risk stratification and tailored treatment of patients with cancer, genetic disorders or disorders of the immune system.
Stock-OncoHelix
Image Credit: Supplied
The second entity will expand Burjeel’s existing research program and analyze the genomic and immune signatures of cancer patients.
As part of an academic role at the University of Calgary, OncoHelix scientists and clinicians are involved in translational research, with more than 350 publications in leading scientific journals. They have developed an “impactful pipeline of precision oncology and immunology” aimed at improving clinical outcomes for cancer patients and transplant recipients.
Burjeel Holdings is one of the largest healthcare service providers in the MENA region with a network of 61 properties including 16 hospitals and 23 medical centers and pharmacies. Its laboratory services division – coLAB – operates a network of 12 laboratories, four of which are accredited by the College of American Pathologists.
OncoHelix has the largest number of clinically validated cancer comprehensive genomic profiling (CGP) panels in Canada.
The new venture will leverage OncoHelix Inc.’s clinical and academic experience to establish a state-of-the-art laboratory through which we will offer testing services not yet widely available in the UAE
-John Sunil, Burjeel Holdings
“We want to strengthen our position as the UAE’s leading provider of comprehensive care and increase our ability to serve the country’s growing medical tourism market,” said John Sunil, CEO of the ADX-listed hospital operator. “Burjeel Holdings continues to invest and form new partnerships to help facilitate the expansion of our translational research programs and improve patient outcomes.”
[ad_2]
Source link